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Burkitt lymphoma (BL) is a very aggressive subtype of non-Hodgkin’s lymphoma that occurs with higher frequency in patients
with HIV/AIDS. Patients with HIV-related BL (HIV-BL) are usually treated with high-intensity, multi-agent chemotherapy
regimens.TheadditionofthemonoclonalantibodyRituximabtochemotherapyhasalsobeenstudiedinthissetting.Thepotential
risks and beneﬁts of commonly used regimens are reviewed herein, along with a discussion of controversial issues in the practical
managementofHIV-BL,includingconcurrentanti-retroviraltherapy,treatmentofrelapsedand/orrefractorydisease,andtherole
of stem cell transplantation.
1.Introduction
Burkitt lymphoma (BL) is a very aggressive subtype of non-
Hodgkin lymphoma (NHL) usually associated with translo-
cation of the MYC oncogene. The World Health Organiza-
tion (WHO) classiﬁcation recognizes three clinical variants
of BL: sporadic, endemic, and immunodeﬁciency related [1].
The last of these is particularly common in patients with
human immunodeﬁciency virus (HIV), in whom the life-
time incidence of BL has been estimated at 10–20% [2],
and wherein it constitutes an acquired immunodeﬁciency-
syndrome- (AIDS-) deﬁning illness.
The diﬀerence in clinical variants of BL may be explained
by variation in stage of B-cell development at which lym-
phomagenesis occurs and by a potential relationship with
Epstein Barr virus (EBV). It has been shown, for instance,
that cases of endemic and AIDS-related BL (both of which
are generally EBV related) have considerably highermutation
rates than those of sporadic BL; EBV-positive BLs also have
higher levels of somatic hypermutation of their variable
region heavy chain genes, and evidence of antigen selection
(whereas EBV-negative BLs generally fail to show this
selection)[3]. These data suggest that EBV-negative BL arises
from an early centroblast, while EBV-positive BL arises later
in development, likely from a memory B cell or late germinal
center B cell. Gene expression signatures of the three variants
also appear to be distinct, with diﬀerences between endemic
and sporadic cases of BL in terms of expression of proteins
that inﬂuence the oncogenic potential of MYC [4], ectopic
expression of which is a near-universal phenomenon in BL.
Historically, HIV/AIDS-related BL (HIV-BL) has repre-
sented a therapeutic challenge, mainly due to (a) the toxicity
involved in treating HIV-positive patients with very intense
and immunosuppressive regimens found to be successful in
HIV-negative patients with BL, (b) the paucity of data from
randomized controlled trials, and (c) the relatively small
number of patients with this disease. As we will explore in
this paper, several paradigms exist with respect to eﬀective
treatment of HIV-BL, though controversies and questions
remain. The goal of this paper is to review the data behind
severalchemotherapeuticregimensanddiscussseveralissues
of particular relevance to this population.2 Advances in Hematology
2. Chemotherapy Regimens
The evolution of therapy for BL (reviewed by Magrath [5])
dates to at least 20 years before the ﬁrst cases of HIV were
reported, and the multiagent regimens devised during that
time have formed the basis for trials in HIV-BL. In the
1970s, it was shown that treatment with short-course, high-
intensity, multiagent chemotherapy, built on a backbone
of cyclophosphamide, vincristine, and methotrexate, could
result in substantial rates of durable remission [6] and that
repeated intrathecal (IT) chemotherapy seemed important
to the prevention of central nervous system (CNS) relapse
[7]. When similar approaches were taken with HIV-positive
patients [8, 9], similarly high rates of complete response
(CR) were achieved. A trend toward inferior 5-year overall
survival (OS) was appreciated in the HIV-positive patients,
and was attributed to delayed complications of HIV, such as
Kaposi’s sarcoma and opportunistic infections. Importantly,
treatment-related toxicity and mortality did not seem to be
appreciably increased in the HIV-positive population. These
datahelpedpavethewayforfurtherinvestigationofintensive
therapy for patients with HIV-BL.
2.1. Hyper-CVAD. In 2002, Cortes et al. [10] reported their
experience using Hyper-CVAD (hyperfractionated cyclo-
phosphamide, vincristine, doxorubicin, and dexamethasone,
in cycles alternating with methotrexate and cytarabine),
along with highly active antiretroviral therapy (HAART) in
patients with AIDS-related Burkitt lymphoma (n = 6) and
leukemia (n = 7). Ten patients were over the age of 35,
and nine were diagnosed with HIV at time of diagnosis of
BL; median CD4+ T-cell (CD4) count was 77/µL. Patients
received a median of 6 cycles of therapy, though over 20%
of cycles were delayed or reduced due to toxicity, and 35%
werecomplicatedbyfeverorinfection.Interestingly,ofseven
patients who were on HAART or started during the ﬁrst
course, six remained alive in CR at time of publication,
whereas all four patients who did not receive HAART died
(three of causes related to progression of HIV-BL).
Thedatafortheadditionofrituximabtothisregimen(R-
Hyper-CVAD) for HIV-BL remains somewhat lacking. The
same group reported improved outcomes using R-Hyper-
CVAD,ascomparedtohistoricalcohortstreatedwithHyper-
CVAD without rituximab [11]. However, 45% of the patients
included were diagnosed with B-cell acute lymphoblastic
leukemia, as opposed to typical BL. When reporting on six
HIV-BLpatientsincludedinthestudy,inabstractformatthe
2003 meeting of the American Society of Clinical Oncology
(ASCO) [12], they noted three deaths in CR due to HIV-
related malignancy or infection.
2.2.CODOX-M/IVAC. Using theCODOX-M/IVAC regimen
(dose-intense cyclophosphamide, doxorubicin, high-dose
methotrexate/ifosfamide, etoposide, and high-dose cytara-
bine) in HIV-negative adults (n = 20) with BL, Magrath and
colleagues reported 100% 2-year EFS [13], but at the cost of
oftensevereneurotoxicity.In2003,Wangandcolleagues[14]
reported their single-institution experience with CODOX-
M/IVAC for patients with HIV-BL. When analyzing HIV-
BL patients treated with CODOX-M/IVAC (n = 8) to those
treated with less intense regimens (n = 6), they noted similar
rates of CR (63% versus 67%, resp.) and 2-year EFS (57%
versus 60%, resp.) in spite of disproportionately more high-
risk patients in the CODOX-M/IVAC cohort (88% versus
33%). Furthermore, when all HIV-BL patients (n = 14) were
analyzed (irrespective of treatment regimen) in comparison
to HIV-negative patients with BL treated in similar fashion
over the same time period (n = 24), HIV status aﬀected rates
of neither CR (HIV-positive patients, 64%; HIV-negative
patients, 63%) nor 2-year EFS (HIV-positive patients, 59%;
HIV-negative patients, 62%). The authors concluded that
CODOX-M/IVAC (a) may overcome high-risk features in
HIV-BL, and (b) did not appear signiﬁcantly more toxic in
patients with HIV-BL as compared to HIV-negative patients
with BL.
CODOX-M/IVAC was subsequently modiﬁed by Lacasce
and colleagues [15] by decreasing the dose of methotrexate,
capping the vincristine dose, modifying the dose schedule
of cyclophosphamide (to permit for earlier use of growth
factor), and increasing the doxorubicin dose, all for the sake
of preserving eﬃcacy while reducing risk of neurotoxicity.
In so doing, the authors realized a 2-year OS of 71% in
HIV-negative patients with BL (n = 14), while observing
seemingly signiﬁcantly lower rates of neurotoxicity. This so-
called “modiﬁed Magrath regimen,” constitutes with slight
additional modiﬁcation (including moving high-dose met-
hotrexate from day 10 to day 15 in order to minimize
toxicity), constitutes the chemotherapeutic backbone of an
ongoing AIDS Malignancy Consortium (AMC) trial (AMC
048), which also adds rituximab to all cycles of therapy. At a
median follow-up of nine months, with 34 patients treated,
the authors reported no treatment-related mortality (TRM)
and one-year OS of 82% [16].
2.3. Dose-Adjusted EPOCH. In spite of the beneﬁcial eﬀects
of HAART upon incidence and outcome of ARL, concerns
remained over the interaction between cytotoxic chemother-
apy and agents included in HAART [17]. With this in mind,
the National Institutes of Health (NIH) explored the use of
infusional dose-adjusted etoposide, prednisone, vincristine,
cyclophosphamide, and doxorubicin (DA-EPOCH) in ARL,
with suspension of HAART for the duration of chemother-
apy (planned 6 cycles) [18]. DA-EPOCH was chosen because
(a) pre-clinical data suggested that sustained concentrations
of doxorubicin, vincristine, and etoposide resulted in rel-
atively less tumor resistance [19], and (b) inter-cycle dose
adjustment permitted for maintenance of dose intensity
while ameliorating toxicity [18]. In this trial, seven of 39
patients (18%) had BL, and those with BL had a signiﬁcantly
higher rate of CNS involvement versus those with diﬀuse
large B-cell lymphoma (DLBCL; 4/7 versus 5/31, resp.,
P = 0.04). Although reporting of the BL subset was oth-
erwise lacking, the trend toward inferior 53-month survival
observed for BL, as compared to DLBCL (43% versus 66%,
P = 0.22), was attributed to the high rate of CNS disease,Advances in Hematology 3
as each patient with BL who died during follow-up was
known to have CNS involvement prior to therapy.
Success with EPOCH led NIH investigators to evaluate
the addition of rituximab to this regimen in HIV-BL. It had
been observed that high levels of response and OS could be
maintained by giving short-course EPOCH with dose-dense
rituximab (SC-EPOCH-RR), with number of courses deter-
mined by interim positron emission tomography-computed
axial tomography (PET-CT) staging, to patients with HIV-
related DLBCL [20]. This so-called “short course” consisted
of three cycles of EPOCH-RR, followed by PET-CT, after
which those with negative results received one additional
cycle, and those with evidence of persistent disease received
an additional 2-3 cycles. In HIV-DLBCL, OS of 73% at
53 months of follow-up was achieved [20]. Based on these
results, the authors turned their attention to PET-CT-di-
rected DA-EPOCH-R in HIV-BL and reported results as
recently as 2009 [21], wherein 8 patients had been treated
with 100% CR rate and OS and no TRM. Results updated
as of September 29, 2011, indicate that each patient was
treated with either three or four total cycles of DA-EPOCH-
RR, and all remain in CR [22]. Of note no patients in this
trial had CNS involvement, and suspension of HAART was a
requirement.
The AMC evaluated the addition of rituximab to DA-
EPOCHforpatientswithnewlydiagnosedARLinarandom-
izedphaseIItrial(AMC034[23]),inwhichpatientsreceived
either rituximab concurrently with each cycle (Arm A) or
weekly for six cycles upon completion of DA-EPOCH (Arm
B). DA-EPOCH was administered for two cycles beyond
CR for a total of between 4 and 6 cycles. Although most
patients had HIV-DLBCL, a signiﬁcant proportion (27/106;
25%) had HIV-BL. When the response rate was analyzed
in all treated patients who had DLBCL, CR occurred in 25
of 35 patients (71%; 95% CI, 54%–85%) in the concurrent
arm and 20 of 44 patients in the sequential arm (46%; 95%
CI, 30%–61%). For those who had Burkitt-like lymphoma
and other highly aggressive subtypes, CR occurred in 10 of
16 patients in the concurrent arm (63%; 95% CI, 35%–
85%) and 9 of 11 patients in the sequential arm (82%;
95% CI, 48%–98%). The study was not powered to evaluate
diﬀerences in patient outcomes between study arms based
upon histology (DLBCL versus BL).
At the 2011 ASCO Annual Meeting, Evans et al. [24]
reported on their single-institution experience using both R-
Hyper-CVAD (n = 7) and R-EPOCH (n = 14) in HIV-BL.
CR was achieved in 43% of patients treated with R-Hyper-
CVAD patients, versus 71% in those treated with R-EPOCH.
Febrile neutropenia was observed in 86% versus 29% of
patients and tumor lysis syndrome (TLS) in 43% versus 14%
of patients for those treated with R-Hyper-CVAD and R-
EPOCH, respectively. The authors interpreted this data as
suggestive of the possibility that R-EPOCH may result in a
higher rate of CR and lower rate of infectious complications
and TLS, when compared to R-Hyper-CVAD.
2.4. PETHEMA Regimen. The Spanish cooperative group
Programa Espanol de Tratamiento en Hematologıa( P E T -
HEMA) reported in 2008 their outcomes in HIV-BL
patients, as treated identically to BL patients without HIV
[25]. Their regimen was based upon one devised and
reported by the German Multicenter Study Group for the
Treatment of Adult Acute Lymphoblastic Leukemia
(GMALL) [26] and relied on a short, intense, non-cross-
resistant cocktail of cytotoxic agents, along with rituximab
(a total of twelve agents are included in the protocol). In the
PETHEMA trial, although three HIV-BL patients died of
infectious causes, the remaining 16 (84%) achieved CR.
This regimen may involve a higher incidence of toxicity, as
18% of HIV-negative patients and 32% of HIV-BL patients
(P = NS) were not able to receive the full 6 cycles of planned
therapy. Nevertheless, neither the 2-year DFS (93%; 95% CI,
82%–99% in HIV-negative and 87%; 95% CI, 72%–99% in
HIV-positive) northe2-yearOS(82%;95%CI,65%–99% in
HIV-negative and 73%; 95% CI, 54%–92% in HIV-positive)
diﬀered signiﬁcantly. CNS involvement was rare in this series
(3/17 among HIV-negative; 1/19 among HIV-positive),
though it was reported by the authors as not impacting
outcome.
Expanded results from use of this regimen in 72 HIV-
BL patients were reported at the ASH 2010 Annual Meeting
[27]. Complete response (CR) was attained in 49pts (81%),
7 (12%) died in induction, and 4 (7%) were resistant. No
relapses were observed after a median follow-up of 2.6 years.
In a multivariate analysis, CD4 count <200/mL and involve-
ment of 2 or more extranodal areas predicted for inferior
r a t e so fC R ,w h i l eC D 4c o u n t<200/mL and Eastern Coop-
erative Oncology Group (ECOG) performance status (PS)
greater than 2 predicted for inferior OS.
3. Areas of Uncertainty
3.1. Rituximab. The use of rituximab in patients with ARL
has garnered controversy since the reporting of AMC 010
[28],inwhichtheriskofinfection-relateddeathsappearedto
oﬀset any beneﬁt of the drug in patients with ARL (80% of
which had DLBCL histology) treated with a chemotherapy
backbone of cyclophosphamide, doxorubicin, vincristine,
and prednisone (CHOP). In AMC 034 [23], among eight
patients with baseline CD4 counts below 50/µL, three
(38%) experienced treatment-related infectious fatalities. A
retrospective review of HIV-BL patients treated with aggres-
sive regimens has questioned whether rituximab improves
outcomes [29].
However, in AMC 034, which had a relatively larger
proportion of patients with HIV-BL as compared to AMC
010, rates of serious infection, and of infection-related death,
were modest and not greater than what would be expected
with EPOCH alone. The incorporation of rituximab into
the PETHEMA regimen corroborates the idea that high cure
rates with modest rates of infectious complications can be
achieved in patients with HIV-BL [27]. Similarly, the safety
data of rituximab plus EPOCH reported in patients with
HIV-DLBCL [20], and implicit in the 100% survival pre-
liminarily reported for those with HIV-BL [22], indicates
that rituximab can be safely given to patients with ARL,4 Advances in Hematology
particularly to those in whom baseline CD4 count is greater
than 50/µL. In the HIV-negative population, the addition of
rituximabappearstoimproveoutcomesinBLwhenaddedto
intensive multiagent chemotherapy [30]. Ultimately, in the
absence of randomized data in patients with HIV-BL (which
is uniformly CD20+), the overwhelming evidence of the
safetyandeﬃcacyoftheadditionofrituximabtochemother-
apy in both HIV-DLBCL and HIV-BL warrants its ongoing
inclusion in protocols for all patients with ARL.
3.2. Relapsed/Refractory Disease and Stem Cell Transplant.
No prospective data is available regarding the treatment
and outcome of relapsed and/or refractory (rel/ref) HIV-BL.
The AMC has conducted a retrospective study of patients
with ARL treated at member institutions [31]a n df o u n d
that of 12 patients with rel/ref HIV-BL, none received stem
cell transplantation (SCT), and only one patient survived
beyond one year, only to succumb to malignancy. A French
report of 14 patients with ARL treated with autologous
SCT (ASCT) included two patients with HIV-BL, both of
whom died within a month of transplant due to refractory
disease [32]. On the other hand, the City of Hope reported
that four of ﬁve HIV-BL patients were alive in CR at
between 20 and 60 months from time of ASCT [33]. In
an ongoing Italian trial of patients with HIV-BL, with a
provisional intensiﬁcation phase that includes ASCT [34],
thirteen patients have been treated with 38-day induction
consisting of methylprednisolone, cyclophosphamide, vin-
cristine, rituximab, methotrexate, VP-16, and doxorubicin,
with IT prophylaxis. Those with <CR after induction were
referred for ASCT. They report successful transplantation
of three such patients, though speciﬁc data regarding EFS
and OS in this small population remains unclear. Another
small series documenting the feasibility of ASCT in ARL
[35] did not specify outcomes for HIV-BL patients. Even in
the HIV-negative population, data regarding management is
scarce. A retrospective evaluation that included 32 patients
with rel/ref BL [36] found that ASCT was associated with 3-
year OS of 37% in chemosensitive disease, but only 7% in
chemoresistantdisease,withmostpatientsinthelattergroup
relapsing and dying within six months.
3.3. Older Patients. P a t i e n t ’ sa g ea b o v e4 0y e a r sh a sb e e n
recognized as a risk factor for poor outcome in BL since at
least 1990 [8]. It also bears noting that, while Magrath et al.
[13] achieved a 100% 2-year OS with CODOX/M-IVAC
when treating adults with median age of 25, a similar regi-
men, when applied to patients with median age of 47 [15],
yielded a seemingly inferior 2-year OS of 71%. Nonetheless,
a recent review of HIV-negative BL suggests that, since the
year 2000, a higher proportion of patients above 40 are being
included in clinical trials and the gap in their prognosis
is narrowing [37]. Although this might suggest that these
“older” patients ought to be treated similarly to younger
adults, it remains unclear whether this holds true for those
with HIV-BL. The reports in patients with HIV-BL that
support the use of Hyper-CVAD [10], DA-EPOCH-RR [22],
andthePETHEMAregimen[25]haveeachincludedpatients
over 40, though none provided outcome data speciﬁc to this
subset. The median age of patients enrolled in the ongoing
AMC 048 trial, as of last report, was age 40 [38], so this may
permit further comparison between HIV-BL patients above
and below this age. Consideration of patient age is likely to
increase in the future, given the recent documented increase
inthenumberofpersonsover40livingwithHIV,whichnow
account for over 40% of the HIV-positive population in the
United States [39].
3.4.CentralNervousSystemInvolvement. IneachoftheHIV-
BL-speciﬁc series discussed above (Table 1), the incidence of
reportedCNSinvolvement waslow,andnoclearconclusions
are apparent with regard to the clinical impact of CNS
involvement at the time of diagnosis. One controlled trial
that predated modern chemotherapy sought to address the
role of CSF prophylaxis in BL (n = 10 each in control and
treatmentarms;allpatientsHIV-negative).Inthistrial,there
was no diﬀerence between the arms in terms of subsequent
development of CNS disease [40]. However, given the
propensity of BL to relapse in with CNS involvement, the
poor outcomes seen in such cases [5, 41], and the relatively
low risk of added toxicity observed with the addition of CNS
prophylaxis, all recent trials/series have employed aggressive
CNS-directed prophylaxis with IT chemotherapy.
3.5. Antiretroviral Therapy and Supportive Care. The use of
HAART appears to improve response to chemotherapy and
clinical outcomes when used in ARL [42] and has been
shown as early as 1996 to be safely administered with infu-
sional CDE (cyclophosphamide, doxorubicin, and etopo-
side) in patients with HIV-related NHL [17]. Although
controlled data is lacking as to the appropriate use of
HAART in HIV-BL, HAART has been included in patients
treatedwithHyper-CVAD[10];theexcellentresultsachieved
with the PETHEMA regimen [25], wherein HAART was
mandatory, seem to weigh in favor of its use. On the other
hand, it bears noting that the NIH has shown that safety and
eﬃcacy can be maintained with suspension of HAART in
patientswithHIV-relatedNHL,duringtheadministrationof
aggressive chemotherapy [18]. Use of Zidovudine is avoided
in HAART regimens for ARL patients due to the risk of
myelosuppression, and deleterious interaction between
HAART agents and chemotherapy, such as that between ten-
ofovir and methotrexate, have been documented [43].
HIV patients are prone to development of BL at
higher CD4 counts as compared to other AIDS-associated
malignancies [44]. However, lower CD4 counts may have
contributed to the higher rates of infectious deaths observed
both in HIV-BL patients treated with Hyper-CVAD [10]a n d
in ARL patients treated on AMC-010 with R-CHOP [28].
Subsequent trials [20, 21, 23] seem to clearly support the
safety and eﬃcacy of aggressive chemotherapy, including
rituximab, in patients with CD4 counts greater than 50/µL.
Rituximab should be held in patients with very low CD4
counts (<50/uL) due to the increased risk of infections as-
sociated with this drug in this subset of patients. Patients on
treatment with rituximab with active hepatitis B (HBV)Advances in Hematology 5
Table 1: Comparison of trials/series including patients with HIV-BL.
Chemotherapy
regimen (reference)
Number of
patients Patient characteristics ORR
(%)
CRR
(%) OS/EFS Comments
Hyper-CVAD [10]1 3
6 with BL, 7 with L3-ALL; 31%
with preexisting HIV; median
CD4: 77/µL 23% CSF+
100 92 48% OS at
2 years
HAART appeared to improve
outcome; CNS ppx: alternating
MTX and Ara-C × 16 total
CODOX-M/IVAC
[14] 8 88% with stage IV disease;
median CD4: 149/µL 21% CSF+ N/A 63 57% EFS
at 2 years
Impact of HAART unclear; CNS
ppx: Ara-C (x2) and MTX with
each cycle
DA-EPOCH-R [21]8
56% with stage III or IV; 76%
with extranodal disease; CD4
count data N/A; proportion
CSF+ N/A
100 100 96% EFS
at 35 mo.
HAART use unclear; CNS ppx:
MTX × 6t o t a l
DA-EPOCH-R [23]
Concurrent 51∗
25% with HIV-BL∗; 79% with
advanced stage; median CD4:
181–194/µL
88 73 70% OS at
2 years CRR for HIV-BL: 63% (10/16)
Sequential 55∗ CNS ppx and HAART at
discretion of treating physician 77 55 67% OS at
2 years CRR for HIV-BL: 82% (9/11)
PETHEMA [25]1 9
58% with stage III or IV; 89%
with preexisting HIV; 58% with
CD4 count >200/µL5 %C S F +
88 88 77% OS at
2 years
HAART mandatory; CNS ppx:
M T X ,A r a - C ,D e x× 8
HIV: human immunodeﬁciency virus; HIV-BL: HIV/AIDS-related Burkitt lymphoma; ORR: overall response rate; CRR: complete response rate; OS: overall
survival; EFS: event-free survival; L3-ALL: Burkitt cell acute lymphoblastic lymphoma; HAART: highly active antiretroviral therapy; CSF: cerebrospinal
ﬂuid; CNS: central nervous system; MTX: methotrexate; Ara-C: cytarabine; Dex: dexamethasone; N/A: not available. Please refer to text for explanation of
chemotherapy regimen abbreviations.
∗Most patients treated as part of AMC 034 had HIV/AIDS-related DLBCL (see text for further explanation).
infections should be treated concurrently with lamivudine
to prevent hepatitis B reactivation. However, single-agent
HBV prophylaxis in the absence of HAART promotes the
emergence of resistant strains of HIV, and the use of
HAART should therefore be strongly recommended in this
population, in accordance with US Department of Health
& Human Services Guidelines [45]. Routine supportive care
for HIV-BL includes prophylaxis against tumor lysis, CNS
disease, and opportunistic infections, especially pneumo-
cystis carinii, fungal infections and mycobacterium avium-
intracellulare. The use of granulocyte colony-stimulating
factors is also recommended beginning 24–48 hours after
treatment until postnadir recovery of white blood cell counts
given the myelosuppressive potential of BL chemotherapy
regimens.
4. Conclusions
No available randomized data directly compare currently
used regimens in BL in either the HIV-positive or HIV-
negative populations. Nevertheless, the trials described in
thispapersuggestthatpatientswithHIVmaybetreatedwith
similar regimens as their HIV-negative counterparts along
with appropriate supportive care. The exception to this are
HIV patients with baseline CD4 counts below 50/µL, as these
patientshavehistoricallybeeneitherexcludedfromreceiving
rituximab in clinical trials or shown to be at signiﬁcant risk
for treatment-related mortality [23].
It remains important to distinguish HIV-BL from HIV-
DLBCL, just as it is essential to distinguish the two his-
tologies in the HIV-negative population. Those with HIV-
BL, for instance, have distinct oncogenic mechanisms [4],
higher rates of CNS involvement [18], and more aggressive
clinical course that warrants more intensive therapy [46], as
compared to those with HIV-DLBCL. As a result of these
diﬀerences, the regimens for HIV-BL tend to carry greater
risks of TRM as compared to those used for HIV-DLBCL,
but with lower rates of late relapse, resulting in long-term
survival rates that tend to approximate 50–80% for either
histology [10, 16, 18, 20, 23–25, 34].
With respect to chemotherapy regimens used in
untreated HIV-BL, several conclusions seem reasonable: (1)
though the number of patients was very small, Hyper-
CVAD appears eﬀective, but may carry an increased risk of
mortality in patients not receiving HAART or with poor per-
formance status. The addition of rituximab to Hyper-CVAD
has not shown signiﬁcantly improved patient outcomes in
HIV-BL. (2) CODOX-M/IVAC is associated with high CR
rates but unacceptable neurotoxicity and myelosuppression.
Modiﬁcation of CODOX-M/IVAC by decreasing the dose of
methotrexate, capping the vincristine dose, modifying the
cyclophosphamide dose schedule, and increasing doxoru-
bicin doses have reduced toxicity while preserving eﬃcacy.
The addition of rituximab to the modiﬁed CODOX-M/IVAC
regimen is under investigation by the AMC. (3) Although
thePETHEMAregimenachievedexcellentclinicaloutcomes,
the addition of rituximab to this or a similar regimen has
not been studied prospectively. In addition, the mandatory
use of HAART in this trial demonstrated the feasibility of
such an approach. (4) Results for the infusional DA-EPOCH
chemotherapy backbone (as reported by both the NIH and6 Advances in Hematology
Table 2: Paradigms in the treatment of HIV/AIDS-related Burkitt lymphoma.
(i) Hyper-CVAD appears eﬀective but may carry an increased risk of mortality in patients not receiving HAART or with poor
performance status. The addition of rituximab to Hyper-CVAD has not shown signiﬁcantly improved patient outcomes in HIV-BL.
(ii) CODOX-M/IVAC is associated with high CR rates but unacceptable neurotoxicity and myelosuppression. Modiﬁcation of
CODOX-M/IVAC has reduced toxicity while preserving eﬃcacy. The addition of rituximab to the modiﬁed CODOX-M/IVAC
regimen is under investigation by the AMC.
(iii) Although the PETHEMA regimen achieved excellent clinical outcomes, the addition of rituximab to this or a similar regimen
has not been studied prospectively.
(iv) Results for the infusional R-EPOCH chemotherapy backbone (as reported by both the NIH and AMC) are promising, with
high CR rates, and warrant further prospective investigation in larger trials.
(v) Patient screening for CNS involvement, along with appropriate CNS prophylaxis, is recommended and is particularly
important with the use of R-EPOCH, as none of the agents in this regimen has signiﬁcant penetration of the CNS.
(vi) There are insuﬃcient data to support autologous stem cell transplantation as initial therapy for HIV-BL patients, though
transplant may beneﬁt a subset of patients with chemosensitive relapsed disease.
(vii) Supportive care for HIV-BL patients is important and includes HAART as well as prophylaxis against tumor lysis syndrome,
CNS relapse, and opportunistic infections.
AMC) are promising, with high CR and OS rates, and
warrant further prospective investigation in larger trials.
In addition, the following tenets of eﬀective therapy,
though lacking the support of randomized data, seem
warranted: patient screening for CNS involvement along
w i t ha p p r o p r i a t eC N Sp r o p h y l a x i si sr e c o m m e n d e da n di s
particularly important with DA-EPOCH, as none of the
agents in this regimen achieves clinically meaningful CNS
penetration. Insuﬃcient data exist to support HDT-ASCT
as initial therapy for HIV-BL or as consolidation therapy for
those in ﬁrst CR, though it may beneﬁt a subset of patients
with chemosensitive relapsed disease. Supportive care for
HIV-BL patients is important and includes HAART, as well
as prophylaxis against tumor lysis syndrome, CNS disease,
and opportunistic infections. The selection of individual
regimens must be made by weighing the risks and beneﬁts
for individual patients.
In closing, Table 2 provides in summarized format what
we believe are some of the most important principles
supportedbyourreviewoftheexistingdataforthetreatment
of HIV-BL.
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